Issue 06 · Longevity
What I Actually Use, What the Evidence Says, and How to Think About Both
"The longevity stack: what I use and what the evidence actually says"
The longevity stack is different from the other peptide protocols in this series. BPC-157 has human clinical reports. GLP-1 agonists have Phase III trials. PT-141 has an FDA approval. The longevity compounds have compelling mechanistic rationale, strong animal data, and in several cases human cell-line confirmation.
What they don't have is randomized controlled trials demonstrating human lifespan extension. Those trials would take fifty years and require endpoints no pharmaceutical company will fund for compounds that can't be patented. They don't exist, and they won't exist for a long time.
What that means: you're working with mechanism + animal evidence + early human signals. That's a reasonable basis for informed personal decisions. It is not the same as established clinical medicine. Know the difference going in.
NAD+ (Nicotinamide Adenine Dinucleotide) is the foundational longevity intervention. Not because it's the most exciting, but because it's the most evidenced, most accessible, and the one that makes everything else work better.
NAD+ is a coenzyme present in every cell — it runs cellular respiration, powers sirtuins (the longevity genes), enables DNA repair, and drives the AMPK/mTOR balance toward repair mode. NAD+ levels fall 40–60% from young adulthood to age 60. That is not a rounding error. The downstream consequences are mitochondrial dysfunction, impaired DNA repair, metabolic inflexibility — directly addressing three major hallmarks.
The oral supplementation options are NMN (500–1000 mg/day) and NR (300–600 mg/day). Both elevate whole-blood NAD+; multiple human trials confirm this. Start here. It's oral, it's well-studied, and it's the base layer for the other compounds.
Epitalon is a four-amino-acid peptide isolated from the pineal gland by Vladimir Khavinson at the St. Petersburg Institute of Biogerontology. It does one thing that nothing else I'm aware of does cleanly: it activates telomerase in somatic cells.
Telomerase is the enzyme that extends telomeres — the chromosomal caps that shorten with every cell division. In most adult cells, telomerase is inactive; telomere shortening is one of the primary aging clocks. Epitalon has been shown in cell culture and rodent studies to activate hTERT expression, the catalytic subunit of telomerase, and to partially restore younger methylation patterns in aging cells.
The evidence is Khavinson's body of work — extensive, mostly published in Russian-language journals, partially translated, not yet widely replicated in Western labs. That evidence gap is real. So is the mechanistic plausibility.
Protocol: 10-day courses at 5–10 mg subcutaneous per day, twice yearly. Short cycles rather than continuous use. This is a relatively low-cost, low-complexity addition for men interested in targeting telomere biology specifically.
What you can actually measure: almost nothing in real time. Biological age testing (epigenetic clock tests) is the most informative available signal if you want data.
MOTS-c is unusual: it's a peptide encoded in mitochondrial DNA, not nuclear DNA. Most of what the human body makes is encoded in the nuclear genome. MOTS-c is a signal that mitochondria send to the rest of the cell — and to other cells — about their functional state.
Discovered in 2015 by Changhan David Lee at USC, MOTS-c activates AMPK through an indirect mechanism involving the folate cycle. AMPK activation drives mitochondrial quality control, suppresses mTOR, improves insulin sensitivity, and reduces inflammaging load. In rodent models: lifespan extension, obesity resistance, improved metabolic markers across the board.
MOTS-c also rises with exercise. Men who train consistently have higher baseline MOTS-c. Exogenous MOTS-c partially replicates that signal — particularly relevant for older or injured individuals who can't generate the signal through exercise volume.
Human trials are early. The animal data is remarkable. Protocol: 5–10 mg subcutaneous, 2–3x/week. This is research-peptide territory; no compounding pathway currently.
GHK-Cu is the copper tripeptide that shows up in your plasma at 200 ng/mL when you're 20 and 80 ng/mL when you're 60. It's also the compound that modulates expression of approximately 4,000 genes — shifting them systematically toward younger expression profiles.
In the longevity context, the relevant effects are: upregulation of DNA repair genes, proteasome activation (protein quality control — loss of proteostasis is a primary hallmark), and downregulation of inflammatory gene networks. GHK-Cu also stimulates collagen synthesis, which is relevant for tissue quality but less specific to longevity biology.
The topical human evidence is solid — strong data on skin collagen and wound healing. The systemic injectable data is limited but mechanistically well-characterized. Both routes can be used simultaneously.
Protocol: topical 1–5% cream daily for skin; subcutaneous 200 mcg–2 mg, 3–5x/week for systemic effects.
SS-31 (Elamipretide) is the most mechanistically precise compound in this stack. It concentrates in the inner mitochondrial membrane and binds cardiolipin — a phospholipid that is essential for the structural integrity of the electron transport chain.
As cardiolipin oxidizes with age, ETC complex activity falls, ATP production declines, and reactive oxygen species increase. SS-31 binds cardiolipin, prevents its oxidation, stabilizes the cristae structure, and directly neutralizes ROS at their primary production site. Multiple studies show restoration of age-related ATP deficits in cardiac, skeletal muscle, and renal tissue.
SS-31 has the most advanced clinical data of any longevity peptide in this stack — Phase II trials in heart failure with preserved ejection fraction, an age-related condition driven significantly by mitochondrial dysfunction. Mixed results in Phase II; further trials underway. The mechanistic case remains compelling.
Protocol: 5–10 mg subcutaneous, 3–5x/week. Limited access; research peptide only.
Not all at once. Here's the rational sequence:
Foundation: NAD+ precursors daily — best evidence, accessible, oral.
Add next: Epitalon (twice-yearly courses) and GHK-Cu topical — both accessible, reasonable evidence, clear protocols.
Advanced tier: MOTS-c and SS-31 once you have the foundation stable — higher cost, earlier evidence stage, injectable.
The longevity stack is not a weekend decision. These are long-term commitments to protocols that operate on timescales of months to years. If you want to track whether any of it is working, run a baseline biological age test (epigenetic clock, available from several commercial labs) before starting and repeat annually.
These compounds target real biology with credible mechanisms and strong animal data. Human lifespan data doesn't exist. You're running a personal experiment with good theoretical grounding. Do it intelligently: baseline testing, one compound at a time, annual biological age tracking.
More is not better. Doing a few things well, consistently, with good sourcing is better than a nine-compound stack you can't afford to maintain and can't evaluate.
Everything I've described in this series — the protocols, the mechanisms, the compounds — only applies when what's in the vial is what it says on the label.
Next issue is sourcing: what the regulatory gap actually means, what can go wrong, what good documentation looks like, and how to tell a reputable vendor from one that's cutting corners. It's the least exciting topic in this series and the most important one to get right before you start.